Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the USFDA for its Injectable facility (F-III) located at Karakhadi. The report follows an inspection conducted between February 9, 2026, and February 18, 2026. This milestone confirms that the facility meets the necessary quality standards as per the regulatory findings, marking a positive development for the company’s manufacturing capabilities.
Successful Regulatory Inspection
Alembic Pharmaceuticals Limited has successfully concluded the USFDA inspection process for its Injectable facility (F-III) situated in Karakhadi. The company received the formal Establishment Inspection Report (EIR) on May 13, 2026, confirming the outcome of the site visit conducted earlier this year.
Inspection Timeline and Compliance
The regulatory review of the Karakhadi plant took place over a ten-day period, spanning from February 9, 2026, to February 18, 2026. The receipt of the EIR indicates that the USFDA has reviewed the inspection findings, providing the company with clarity regarding the operational status and compliance standing of this specific facility.
Impact on Operations
The Injectable facility (F-III) remains a key component of the company’s production infrastructure. By receiving this report, Alembic Pharmaceuticals reaffirms its commitment to maintaining rigorous global quality standards across its manufacturing sites, ensuring continued readiness to supply its injectable product portfolio to international markets.
Source: BSE
